Kyras Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Kyras Therapeutics General Information

Description

Developer of drugs designed to cure cancer and other developmental disorders. The company's drugs address currently incurable cancers and developmental disorders caused by RAS gene mutations, enabling healthcare providers to cure their patients.

Contact Information

Website
www.kyrasrx.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 430 East 29th Street
  • Suite 1005
  • New York, NY 10016
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 430 East 29th Street
  • Suite 1005
  • New York, NY 10016
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kyras Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Apr-2018 000 Completed Out of Business
3. Grant 16-Nov-2017 000 000 Completed Generating Revenue
2. Early Stage VC (Series A) 10-Dec-2015 $5M $5M 0000 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Kyras Therapeutics’s complete valuation and funding history, request access »

Kyras Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00 00.000
To view Kyras Therapeutics’s complete cap table history, request access »

Kyras Therapeutics Patents

  • 1

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Kyras Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170158702-A1 Multivalent ras binding compounds Inactive 02-Dec-2015 0000000000

Kyras Therapeutics Executive Team (3)

Name Title Board Seat
Carlo Rizzuto Ph.D Co-Founder, Board Member & Chief Executive Officer
Joseph Vacca Ph.D Chief Scientific Officer
You’re viewing 2 of 3 executive team members. Get the full list »

Kyras Therapeutics Board Members (3)

Name Representing Role Since
Bradley Bolzon Ph.D Versant Ventures Board Member 000 0000
Carlo Rizzuto Ph.D Self Co-Founder, Board Member & Chief Executive Officer 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Ready to get started?

Request a free trial

Kyras Therapeutics FAQs

  • When was Kyras Therapeutics founded?

    Kyras Therapeutics was founded in 2015.

  • Who is the founder of Kyras Therapeutics?

    Carlo Rizzuto Ph.D and Brent Stockwell Ph.D are the founders of Kyras Therapeutics.

  • Who is the CEO of Kyras Therapeutics?

    Carlo Rizzuto Ph.D is the CEO of Kyras Therapeutics.

  • Where is Kyras Therapeutics headquartered?

    Kyras Therapeutics is headquartered in New York, NY.

  • What industry is Kyras Therapeutics in?

    Kyras Therapeutics’s primary industry is Drug Discovery.

  • Is Kyras Therapeutics a private or public company?

    Kyras Therapeutics is a Private company.

  • What is Kyras Therapeutics’s current revenue?

    The current revenue for Kyras Therapeutics is 000000.

  • How much funding has Kyras Therapeutics raised over time?

    Kyras Therapeutics has raised $5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »